Syngene International Limited has announced comprehensive changes to its senior management team, involving the departure of three key executives and the appointment of two new senior leaders. The changes, disclosed under Regulation 30 of SEBI Listing Regulations on March 6, 2026, will take effect between April 30 and May 1, 2026.

Executive Departures

Three senior management personnel will be leaving the company by mutual consent on April 30, 2026:

All three executives are members of the Executive Committee and hold Senior Management Personnel positions within the organization.

New Leadership Appointments

The company has announced two strategic appointments to fill key positions effective May 1, 2026:

Chief Commercial Officer - Mr. Abhijit Zutshi

Mr. Abhijit Zutshi will assume the role of Chief Commercial Officer and become a member of the Executive Committee. He brings over two decades of experience at Biocon Limited, where he currently serves as Chief Commercial Officer with responsibility for Generics business Commercial operations.

Key highlights of his experience:

• Successful leadership across marketing, sales, business development and portfolio selection for small molecules and biologics
• Previously served as Commercial Head of Global Generics Formulations
• Instrumental in establishing commercial infrastructure in the U.S. for Biocon's formulation business
• Led the successful launch of Biocon's first generic formulation in the U.S. in 2017
• Former head of Biocon's North American operations
• Prior experience with Pfizer as a product specialist
• Educational background includes a bachelor's degree in Pharmaceutical Science with Pharmacology major, Diploma in Business Management, and Harvard Business School's Program for Leadership Development

Chief Human Resources Officer - Ms. Maninder Singh Puri

Ms. Maninder Singh Puri will take on the role of Chief Human Resources Officer and join the Executive Committee as Senior Management Personnel.

Professional background:

• Currently serves as Head of Human Resources for Generics Business and Biocon Academy
• Over 25 years of professional experience in leadership positions
• Former Global Chief Human Resources and Diversity Officer at Mastek Group
• Previous roles with Accenture, iGATE (now Cap Gemini), and Firstsource Solutions
• Recognized as "CHRO for the year 2022"
• Educational qualifications include Masters in English Literature and CHRO degree from Wharton Business School
• Passionate advocate for Diversity, Equity, Inclusion and Belonging (DEIB)

Regulatory Compliance

The management changes were disclosed in compliance with Regulation 30 read with Para A (7) of Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has confirmed that detailed information regarding these changes will be made available on its official website at www.syngeneintl.com .

These leadership transitions reflect the company's strategic approach to maintaining operational continuity while bringing in experienced professionals to drive future growth initiatives.

Syngene International has received partial relief from the National Faceless Appeal Centre (NFAC) in ongoing tax litigation matters spanning multiple assessment years. The company disclosed this development through a regulatory filing dated February 14, 2026, in compliance with SEBI Listing Regulations.

Tax Appeal Orders and Timeline

The NFAC passed orders dated February 13, 2026, under section 250 of the Income-tax Act, 1961, providing partial relief to the company. These orders relate to appeals filed against additions and disallowances made by the Assessing Officer during assessment completion for three specific years.

Background of Tax Disputes

The tax disputes originated when the Assessing Officer made additions and disallowances of certain deductions claimed by the company during assessment completion under section 143(3) of the Income-tax Act. The company subsequently filed appeals against these orders on the dates mentioned above, challenging the additions and disallowances.

Expected Financial Impact

According to the company's disclosure, the management believes there may not be material impact on the company's financials, operations, or activities. However, the company expects positive outcomes from these orders:

• Reduction in contingent liability
• Eligibility for refunds

The Assessing Officer will now pass an order giving effect to the NFAC's decision, which should formalize these expected benefits.

Regulatory Compliance Details

The company received notification of these orders through SMS and subsequently downloaded them from the Income tax website on February 14, 2026. The disclosure was made in accordance with:

• Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015
• SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026
• Industry Standards Note on Regulation 30 dated February 25, 2025

Current Status and Next Steps

The company has confirmed that no penalties, restrictions, or sanctions were imposed in the current orders dated February 13, 2026. Management stated that the company is in the process of analyzing the orders passed and will take appropriate action as necessary. The orders represent a significant development in tax matters that have been pending for several years, with some appeals dating back to 2016.